StreetInsider.com News Articles

ORIC Pharmaceuticals (ORIC) PT Raised to $26 at JPMorgan

Wed, 14 Oct 2026 08:48:04 -0400

JPMorgan analyst Anupam Rama raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $26.00 (from $23.00) while maintaining a Overweight rating.

ORIC Pharmaceuticals partners with Cancer Research UK on cancer drug

Mon, 05 Oct 2026 16:03:13 -0400

ORIC Pharmaceuticals (Nasdaq: ORIC) has signed an agreement with Cancer Research UK to advance ORIC-259, a small molecule drug candidate targeting CIP2A, into clinical development, according to a press release from the company.

Under the agreement, Cancer Research UK's Centre for Drug Development will fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259 for cancer patients. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties.

ORIC-259 is described by the company as a potent, selective, orally bioavailable small molecule degrader

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Mon, 05 Oct 2026 16:01:00 -0400

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Mon, 05 Oct 2026 16:01:00 -0400

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

Leerink Starts ORIC Pharmaceuticals (ORIC) at Outperform

Mon, 05 Oct 2026 06:09:43 -0400

Leerink analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Outperform rating and a price target of $26.00.

For an analyst ratings summary and ratings history on ORIC Pharmaceuticals click here. For more ratings news on ORIC Pharmaceuticals click here.

Shares of ORIC Pharmaceuticals closed at $12.21 yesterday.

Form 4 Oric Pharmaceuticals, For: Oct 01 Filed by: Heyman Richard A.

Fri, 02 Oct 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20261002/27143774.html

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Thu, 01 Oct 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20261001/27136323.html

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Thu, 01 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261001/27136310.html

Form 4 Oric Pharmaceuticals, For: Sep 28 Filed by: Piscitelli Dominic

Tue, 29 Sep 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260929/27123755.html

Form 4 Oric Pharmaceuticals, For: Sep 24 Filed by: Piscitelli Dominic

Fri, 25 Sep 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20260925/27108429.html

BTIG Starts ORIC Pharmaceuticals (ORIC) at Buy

Wed, 23 Sep 2026 06:05:44 -0400

BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Buy rating and a price target of $26.00.

The analyst comments "ORIC Pharmaceuticals is a clinical-stage oncology company developing lead program rinzimetostat, an allosteric inhibitor of the EED subunit of PRC2 in post-abiraterone mCRPC, and enozertinib, a brain-penetrant EGFR TKI for ex20ins and PACC-mutant NSCLC. The investment thesis centers on rinzimetostat's potential best-in-class safety profile over Pfizer's (PFE, Not Rated) mevrometostat, which has an upcoming ph 3 MEVPRO-1 readout that could de-risk the PRC2 pathway in 4Q26 and give positive read through to ORIC's stock. The company plans

BTIG Starts ORIC Pharmaceuticals (ORIC) at Buy

Wed, 23 Sep 2026 06:05:44 -0400

BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Buy rating and a price target of $26.00.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the “Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:30:00 -0400

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:

Wells Fargo 21^stAnnual Healthcare Conference – Participating in a fireside chat on Wednesday, September 9, 2026, at 2:15 p.m. ET. Management will also be participating in one-on-one meetings.
2026 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

Wells Fargo 21^stAnnual Healthcare Conference – Participating in a fireside chat on Wednesday, September 9, 2026, at 2:15 p.m. ET. Management will also be participating in one-on-one meetings.
2026 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September

Form 4 Oric Pharmaceuticals, For: Aug 26 Filed by: Piscitelli Dominic

Fri, 28 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26998006.html

Form 4 Oric Pharmaceuticals, For: Aug 26 Filed by: Piscitelli Dominic

Fri, 28 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26998006.html

Form 144 Oric Pharmaceuticals, Filed by: Piscitelli Dominic

Wed, 26 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26981811.html

Form 144 Oric Pharmaceuticals, Filed by: Piscitelli Dominic

Wed, 26 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26981811.html

ORIC Pharmaceuticals (ORIC) PT Raised to $27 at H.C. Wainwright

Mon, 10 Aug 2026 06:53:38 -0400

(Updated - August 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $27.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "As we look into 2H26, we note a catalyst-rich year for ORIC, which includes: (1) a program update for ORIC-944 in 2H26 (see our prior note for our thoughts on the dose-optimization results released earlier this year); (2) presentation of updated data for enozertinib monotherapy in 1L EGFR exon 20 insertion-positive NSCLC and initial results for the combination with subcutaneous amivantamab in 2H26. Recall, per the December 2025

ORIC Pharmaceuticals (ORIC) PT Raised to $27 at H.C. Wainwright

Mon, 10 Aug 2026 06:53:38 -0400

(Updated - August 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $27.00 (from $25.00) while maintaining a Buy rating.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who began their employment with ORIC in July 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each